Corporate | 20 March 2014 11:50
DGAP-News: BioPorto A/S /
20.03.2014 / 11:50
---------------------------------------------------------------------
BioPorto Diagnostics is proud to announce that we have established a prominent
European Scientific Advisory Board, and we will host the first meeting in
Brussels May 2014 with next meeting planned in the Autumn of 2014. We have
received acceptance from a group of renowned and leading acute kidney injury
(AKI) specialists from cardiac, nephrology and ICU medical areas. Our Board
members will challenge current published knowledge and by applying their
experience and expertise, the goal is to move current knowledge to a higher
level. Ultimately, the aim will be to identify and set forth sound clinical
practical approaches that will lead the way for improvements of AKI
diagnostics.
The Scientific Advisory Board members are:
Prof. Dr. med Jean-Louis Vincent, Erasme, Belgium. (Chair)
-- Assoc. Prof. Dr. med Andrew Lewington, St. James's University Hospital,
Leeds, UK.
(Vice Chair)
-- Director Dr. med Claudio Ronco, San Bortolo Hospital, Vicenza, Italy
-- Prof. Dr. med Laurent Jacob, Saint-Louis Hospital, Paris, France
-- Prof. Dr. med Michael Haase, Otto-von.Guericke University, Magdeburg,
Germany
-- Dr. med, PhD, Hilde RH DE Geus, Eramus University Medical Center Rotterdam,
NL
Acute kidney injury is a syndrome that affects patients across several medical
and surgical specialties, and is a syndrome with poor outcome. The Scientific
Advisory Board meetings will address the challenges and unmet needs for AKI
diagnostics within a specific medical area at bi-annual meetings.
Meetings in 2014 will address AKI and neutrophil gelatinase-associated
lipocalin (NGAL) biomarker challenges and opportunities within two major
surgical specialties: Kidney Transplantation and Cardiopulmonary Bypass (CPB)
procedures.
For questions or comments, please contact CEO Peter M. Eriksen or Marketing
Manager Thomas Lowes
Tel.: +45 4529 0000
info@bioporto.com
About BioPorto Diagnostics A/S
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales channels and
partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on
the NASDAQ OMX: BIOPOR Copenhagen stock exchange.
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=465177
News Source: NASDAQ OMX
End of Corporate News
---------------------------------------------------------------------
20.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: BioPorto A/S
Dänemark
ISIN: DK0011048619
End of News DGAP News-Service
---------------------------------------------------------------------
258650 20.03.2014